Clinical Trials Logo

Intestinal Diseases clinical trials

View clinical trials related to Intestinal Diseases.

Filter by:

NCT ID: NCT04291976 Completed - Clinical trials for Inflammatory Bowel Diseases

Back-to-back Endoscopy Versus Single-pass Endoscopy and Chromoendoscopy in IBD Surveillance

HELIOS
Start date: March 13, 2020
Phase: N/A
Study type: Interventional

The current international guidelines for CRC surveillance in IBD recommend as first choice the use of chromoendoscopy, and as an alternative high-definition white light endoscopy (HDWLE) for optimal dysplasia detection, based on data from clinical trials. However, data on the superiority of CE over HDWLE are not consistent in literature. The investigators hypothesize that the better performance of CE in some clinical trials is the result of the associated longer procedural time and the fact that every colon segment is examined twice. Currently, no studies have been published evaluating the dysplastic yield of back-to back HDWLE compared to HDWLE with a single pass or CE in patients with IBD. In the present study, the investigators aim to compare the yield of dysplasia/CRC between 1) regular HDWLE, 2) HDWLE back-to-back, and 3) CE.

NCT ID: NCT04263818 Completed - Colonic Diseases Clinical Trials

Endoscopist and Endoscope Motions During Colonoscopy

ScopeGuide
Start date: June 5, 2020
Phase: N/A
Study type: Interventional

The aim of the study is to record and analyze endoscopist and endoscope motions to identify key movements during colonoscopy.

NCT ID: NCT04256538 Completed - Clinical trials for Inflammatory Bowel Diseases

Identify Specific Peripheral Blood Mononuclear Cell (PBMC) MiRNA as Biomarkers for Inflammatory Bowel Disease (IBD)

Start date: August 15, 2019
Phase:
Study type: Observational [Patient Registry]

To find high sensitivity and specificity biomarkers to better diagnose and monitor progression of inflammatory bowel disease (IBD). In this study, we try to find miRNAs that can used to diagnose or monitor progression of IBD by exploring differential expression of miRNAs in peripheral blood mononuclear cells (PBMCs) from Crohn's disease, ulcerative colitis and healthy controls. And we further validate these miRNAs in a larger population to assess their function as biomarkers.

NCT ID: NCT04254614 Completed - Clinical trials for Inflammatory Bowel Diseases

Mobile Application for IBD Patients With Biologics

Start date: March 12, 2020
Phase: N/A
Study type: Interventional

Monitoring of biologic treatment in patients with inflammatory bowel disease (IBD) is important given the increased risk of infections. In this study we aim to evaluate the use of a mobile application to guide IBD patients and facilitate the monitoring of biologic treatment.

NCT ID: NCT04213833 Completed - Clinical trials for Gastro-Intestinal Disorder

Effect of Palatable Lidocaine Gel on Gag Reflex for Patients Undergoing Upper Gastrointestinal Endoscopy

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

- The development of upper gastrointestinal endoscopy (UGIE) has greatly expanded the diagnostic and therapeutic capabilities of gastroenterologists. The patient's tolerance to procedure and endoscopist's satisfaction increase when sedation is used along with topical pharyngeal anesthesia. - Numerous agents are available for moderate sedation in endoscopy such as propofol, midazolam, ketamine, fentanyl and dexmedetomidine, the choice of a particular sedative agent depends on its availability, cost and experience of the endoscopist and patient with that sedative agent. However, these i.v. anesthetics may be associated with complications especially in elderly patients or in those with other comorbidities, as apnea, hypoxia, hypotension, and paradoxical agitation, in which the patient becomes agitated rather than sleepy from the sedation, leading to increased morbidity and the duration of the patient's hospitalization. - Local application of lidocaine to the oral cavity and the oropharynx, will attenuate or even abolish the gag reflex increasing the patient's comfort thus decreasing the dose of i.v. anesthetics with their potential complications. - Up to our knowledge, there is no study done to evaluate the effect of palatable lidocaine gel versus I .v dexmedetomidine on the incidence of gag reflex and total propofol consumption during elective upper gastrointestinal endoscopy.

NCT ID: NCT04209634 Completed - Clinical trials for CD55-deficient Protein-losing Enteropathy

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Start date: January 27, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE). The secondary objectives of the study are: - To evaluate the safety and tolerability of pozelimab in patients with CD55-deficient PLE disease - To evaluate the effect of pozelimab on CD55-deficient PLE (both patients with active disease at baseline and those with inactive disease on eculizumab, switching to pozelimab) - To determine the effects of pozelimab on albumin and other serum proteins (total protein, immunoglobulins) - To determine the effects of pozelimab on ascites - To determine the effects of pozelimab on stool consistency - To determine the effect of pozelimab on health-related quality of life - To determine the effect of pozelimab on lab abnormalities observed in CD55-deficient PLE such as hypertriglyceridemia, thrombocytosis, and hypovitaminosis B12 - To describe the effects of pozelimab on the sparing of concomitant medications and reduction in hospitalization days - To determine the effects of pozelimab on growth - To characterize the concentration of pozelimab in patients with CD55-deficient PLE - To assess the incidence of treatment-emergent ADA for pozelimab in patients with CD55-deficient PLE disease

NCT ID: NCT04191707 Completed - Ulcerative Colitis Clinical Trials

Metabolomic Markers of Fatigue in Inflammatory Bowel Disease

Start date: November 1, 2013
Phase:
Study type: Observational

Fatigue is a common symptom and a leading concern in patients with inflammatory bowel disease (IBD) and often persists despite clinical and endoscopic remission. This study evaluates the metabolomic profile of fatigued patients with IBD.

NCT ID: NCT04190108 Completed - Clinical trials for Inflammatory Bowel Diseases

Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis.

Start date: January 2, 2016
Phase:
Study type: Observational

Background.Recent epidemiologic studies have shown an association between psoriasis, psoriatic arthritis (PsA) and inflammatory bowel diseases (IBD). Recently, measurement of fecal calprotectin (FC) demonstrated a good sensitivity and specificity for intestinal inflammation. Primary objective of present study was to evaluate the presence of occult bowel inflammation in patients with PsA as expressed by elevated levels of FC. Secondary objectives were to investigate the correlation between the levels FC and clinical and laboratory features, and the outcome of CF-positive patients in terms of IBD development.

NCT ID: NCT04186390 Completed - Education Clinical Trials

Learning Small Bowel Capsule Endoscopy

Start date: October 29, 2018
Phase:
Study type: Observational

This project is a prospective study investigating the education of medical doctors in gastroenterology with no prior experience to evaluate small bowel capsule endoscopies with a diagnostic sensitivity >90%

NCT ID: NCT04134104 Completed - Sexual Dysfunction Clinical Trials

Incidence of The Bowel, Bladder, and Sexual Dysfunction Following Surgery for Colorectal Malignancy

Start date: December 2014
Phase:
Study type: Observational [Patient Registry]

Colorectal cancer is the second most common cancer by the site in Europe and the third most common cancer in the USA with high morbidity and mortality. Survival after the treatment has improved over the past few decades as a result of early diagnosis, radiotherapy, and advances in surgical techniques such as abdominoperineal resection (APR), low anterior resection (LAR) and total mesorectal excision (TME). These innovative surgeries are the current standard treatment for the mid and the low rectal cancers which avoids the permanent colostomy. It is very difficult to find out the incidence of the bowel, bladder and sexual dysfunction of patients either because they are embarrassed or because they do not relate their symptoms to rectal cancer treatment. This article reports the incidence of the bowel, bladder and sexual dysfunction following surgery for rectal cancer from the National Academy of Medical Sciences, Bir Hospital, a tertiary level hospital.